Top 10 Selling Drugs in the World 2025
The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025.
Among the top ten best-selling drugs forecasted, three belong to the GLP-1 class, all of which fall under metabolic therapy. Additionally, two autoimmune drugs, Dupixent (dupilumab) and Skyrizi (risankizumab), remain regulars on the best-seller list, ranking fourth and seventh, respectively.
Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year. The strong growth in pembrolizumab's sales is attributed to the continuous expansion of its indications.
GLP-1 receptor agonists dominate the metabolic therapy segment with three drugs in the top 10: Ozempic and Wegovy (both semaglutide-based) and Mounjaro (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic diseases. Eli Lilly announced in October 2023 that results from the SURMOUNT-3 phase III clinical trial showed tirzepatide's weight loss effect was superior to semaglutide, drawing widespread attention.
Dupixent (dupilumab) and Skyrizi (risankizumab) are prominent autoimmune therapies, addressing conditions like atopic dermatitis, asthma, psoriasis, and Crohn’s disease, maintaining strong market positions with combined sales near $30 billion.
Eliquis (apixaban), an anticoagulant, continues to be a top seller due to its widespread use in stroke prevention for atrial fibrillation and treatment of thromboembolic disorders.
HIV treatment Biktarvy and cancer drug Darzalex also maintain high sales, each expected around $13 billion, underscoring continued demand in infectious disease and oncology.
The 2025 pharmaceutical sales landscape is led by innovative immunotherapies and metabolic drugs that address some of the largest global health burdens—cancer, diabetes, obesity, and autoimmune diseases. Merck’s Keytruda solidifies its position as the top-selling drug worldwide, while Novo Nordisk and Eli Lilly capture significant market shares in metabolic therapies. The sustained success of these drugs highlights the pharmaceutical industry's focus on chronic and complex diseases with high unmet medical needs.
1. Keytruda (Merck)
2. Ozempic (Novo Nordisk)
3. Mounjaro (ELi Lilly)
4. Dupixent (Sanofi and Regeneron)
5. Wegovy (Novo Nordisk)
6. Biktarvy (Gilead Sciences)
7. Skyrizi (Abbvie)
8. Eliquis (Bristol-Myers Squibb)
9. Darzalex (Johnson & Johnson)
10. Humira (Abbvie)
Among the top ten best-selling drugs forecasted, three belong to the GLP-1 class, all of which fall under metabolic therapy. Additionally, two autoimmune drugs, Dupixent (dupilumab) and Skyrizi (risankizumab), remain regulars on the best-seller list, ranking fourth and seventh, respectively.
Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year. The strong growth in pembrolizumab's sales is attributed to the continuous expansion of its indications.
GLP-1 receptor agonists dominate the metabolic therapy segment with three drugs in the top 10: Ozempic and Wegovy (both semaglutide-based) and Mounjaro (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic diseases. Eli Lilly announced in October 2023 that results from the SURMOUNT-3 phase III clinical trial showed tirzepatide's weight loss effect was superior to semaglutide, drawing widespread attention.
Dupixent (dupilumab) and Skyrizi (risankizumab) are prominent autoimmune therapies, addressing conditions like atopic dermatitis, asthma, psoriasis, and Crohn’s disease, maintaining strong market positions with combined sales near $30 billion.
Eliquis (apixaban), an anticoagulant, continues to be a top seller due to its widespread use in stroke prevention for atrial fibrillation and treatment of thromboembolic disorders.
HIV treatment Biktarvy and cancer drug Darzalex also maintain high sales, each expected around $13 billion, underscoring continued demand in infectious disease and oncology.
Sources:
.png)
.png)
%20in%20a%20visually%20appealing%20way,%20without%20any%20text.%20The%20background%20is%20split_%20one%20side%20has%20a%20sci.webp)
.png)
.png)
.png)
Comments
Post a Comment